• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HLG
Click for more information
0.42% $7.13

Hallenstein Glasson Holdings Limited Ordinary Shares - Charts / Financials

watchlist Created with Sketch. Add to my watchlist
Consumer Cyclical

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Day
Open $7.10   Day High $7.14   Day Low $7.01
Daily Volume 23973
Bids   Sellers
Number Price Volume   Number Price Volume
0 $7.12 367   0 $7.13 1388

Data source: Refinitiv

(20min delay)
Last
$7.13 		Change
0.030(0.42%) 		Mkt cap ! n/a
Open High Low Value Volume
$7.10 $7.14 $7.01 $170.1K 23.97K

Buyers (Bids)

No. Vol. Price($)
0 367 $7.12
 

Sellers (Offers)

Price($) Vol. No.
$7.13 1388 0
Last trade - 07.23am 04/10/2024 (20 minute delay) ?

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Neurotech International (NTI) has flagged to its shareholders that the FDA hasn't granted its product NTI164 orphan drug status.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation Rox Resources Ltd has extended the mineralisation of its Paddy's Lode prospect in Western Australia through diamond drilling
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.